Aimmune Therapeutics Inc. (AIMT) and Tiziana Life Sciences PLC (NASDAQ:TLSA) Comparing side by side

Since Aimmune Therapeutics Inc. (NASDAQ:AIMT) and Tiziana Life Sciences PLC (NASDAQ:TLSA) are part of the Biotechnology industry, they are influenced by contrast. The influences particularly affect the profitability, analyst recommendations, risk, dividends, institutional ownership, earnings and valuation of both companies.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Aimmune Therapeutics Inc. N/A 0.00 215.52M -3.62 0.00
Tiziana Life Sciences PLC N/A 0.00 N/A -0.07 0.00

Table 1 highlights Aimmune Therapeutics Inc. and Tiziana Life Sciences PLC’s gross revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 shows us the return on equity, return on assets and net margins of both businesses.

Net Margins Return on Equity Return on Assets
Aimmune Therapeutics Inc. 0.00% -79.1% -66.4%
Tiziana Life Sciences PLC 0.00% 0% 0%

Insider & Institutional Ownership

The shares of both Aimmune Therapeutics Inc. and Tiziana Life Sciences PLC are owned by institutional investors at 84.8% and 2.82% respectively. Insiders owned roughly 0.4% of Aimmune Therapeutics Inc.’s shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Aimmune Therapeutics Inc. 4.56% -3.24% -12.31% -31.07% -30.72% -12.71%
Tiziana Life Sciences PLC 8.14% 16.66% 14.09% 0% 0% 14.09%

For the past year Aimmune Therapeutics Inc. has -12.71% weaker performance while Tiziana Life Sciences PLC has 14.09% stronger performance.

Summary

Tiziana Life Sciences PLC beats on 5 of the 6 factors Aimmune Therapeutics Inc.

Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies in the United States and Europe. Its lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy. Aimmune Therapeutics, Inc. has strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. The company was founded in 2011 and is headquartered in Brisbane, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.